Advertisement

Retardierte Arzneiformen von Nitraten des Isosorbids: Modetrend oder therapeutische Notwendigkeit?

  • U. Abshagen
  • H.-J. Überbacher

Zusammenfassung

Nitrate des Isosorbids, die Eingang in die Therapie gefunden haben, sind das seit mehr als 30 Jahren verwendete Isosorbiddinitrat und das Ende 1981 erstmals in Deutschland eingeführte Isosorbid-5-Mononitrat. Prüfstein für die Beantwortung der gestellten Frage sind letztlich kontrollierte Studien zur therapeutischen Wirksamkeit nicht retardierter und retardierter Arzneiformen mit unterschiedlichen Dosisregimen beider Substanzen. Dies wird daher den Hauptteil der Darlegungen ausmachen, wobei wir uns auf die antianginöse Wirksamkeit beschränken wollen. Ausgangspunkt und rationale Basis der klinischen Anwendung bilden jedoch pharmakokinetische Kenngrößen beider Substanzen und ihrer unterschiedlichen Darreichungsformen. Hiermit sei deshalb begonnen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Frydman, A., Levenson, J., Simon, A., Safar, M., Bieder, A., Bertharion, J., Gaillor, J. (1982), Pharmacocinetique du dinitrate d’isosorbide. Nouv. Presse Med. 11: 2049–2056.PubMedGoogle Scholar
  2. [2]
    Platzer, R., Reutemann, G., Galeazzi, R. L. (1982), Pharmacokinetics of intravenous isosorbide-dinitrate. J. Pharmacokinet. Biopharm. 10: 575–585.PubMedCrossRefGoogle Scholar
  3. [3]
    Taylor, T., Chasseaud, L. F., Doyle, E., Bonn, R., Darragh, A., Lambe, R. F. (1982), Isosorbide dinitrate pharmacokinetics. Arzneimittelforsch/Drug Res. 32: 1329–1333.Google Scholar
  4. [4]
    Morrison, R. A., Wiegand, U. W., Jähnchen, E., Höhmann, M. D., Bechthold, H., Meinertz, T., Fung, H. L. (1983a), Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina. Clin. Pharmacol. Ther. 33: 747–756.PubMedCrossRefGoogle Scholar
  5. [5]
    Fung, H. L., Sutton, C. and Kamiya, A. (1985), Vascular pharmacokinetics of nitrates. In: J. N. Cohn and R. Rittinghausen (eds.) Mononitrates (International Boehringer Mannheim Symposia, Montreux 1984), Springer-Verlag Berlin, Heidelberg, New York, Tokyo, 67–72.Google Scholar
  6. [6]
    Abshagen, U. (1985a), Pharmacokinetics of ISDN, sustained-release ISDN, and IS-5-MN. In: J. N. Cohn and R. Rittinghausen (eds.) Mononitrates (International Boehringer Mannheim Symposia, Montreux 1984), Springer-Verlag Berlin, Heidelberg, New York, Tokyo, 53–56.Google Scholar
  7. [7]
    Spörl-Radun, S, Betzien, G., Kaufmann, B., Liede, V., Abshagen, U. (1980), Effects and pharmacokinetics of isosorbide dinitrate in normal man. Eur. J. Clin. Pharmacol. 18: 237–244.PubMedCrossRefGoogle Scholar
  8. [8]
    Assinder, D. F., Chasseaud, L. F., Taylor, T. (1977), Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations. J. Pharm. Sci. 66: 775–778.PubMedCrossRefGoogle Scholar
  9. [9]
    Laufen, H., Scharpf, F., Bartsch, G. (1978), Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies. J. Chromatogr. 146: 457–464.PubMedCrossRefGoogle Scholar
  10. [10]
    Chasseaud, L. F., Taylor, T. (1980), Plasma concentrations and comparative bioavailability of isosorbide dinitrate after sublingual, oral or cutaneous doses to human subjects. In: Rudolph, W., Schrey, A. (eds.), Nitrate II. Urban and Schwarzenberg, Munich, Vienna, Baltimore, 22.Google Scholar
  11. [11]
    Abshagen, U., Betzien, G., Endele, R., Kaufmann, B., and Neugebauer, G. (1985b), Pharmacokinetics and metabolism of isosorbidedinitrate after intravenous and oral administration. Eur. J. Clin. Pharmacol. 27: 637–644.PubMedCrossRefGoogle Scholar
  12. [12]
    Steinbach, D. und Müller, H. (1978), Untersuchungen zur Dosierungsgenauigkeit und Wirkstoff-Freisetzung von Isosorbiddinitrat-Retard-präparaten. Pharmazeutische Zeitung Nr. 12: 475–480.Google Scholar
  13. [13]
    Gladigau, V., Neurath, G., Dünger, M., Schnelle, K., Johnson, K. I. (1981), Plasma levels of isosorbide dinitrate and its main metabolites following oral administration of two sustained release formulations in normal man. Arzneimittelforsch./Drug Res. 31: 835–840.Google Scholar
  14. [14]
    Geigenberger, A., Degen, J., Maier-Lenz, H. (1982), Vergleichende Pharmakokinetik und Bioverfügbarkeit von Isosorbiddinitrat und seiner Metaboliten 5-und 2-Isosorbidmononitrat aus zwei Retardpräparaten. Arzneimittelforsch/Drug Res. 32: 1138–1140.Google Scholar
  15. [15]
    Rietbrock, N., Knoll, J., Merz, P.-G., Menke, G. (1985), Bioverfügbarkeit von Isosorbiddinitrat und Isosorbid-5-Mononitrat unter steady-state-Bedingungen. Dtsch. med. Wschr. (im Druck).Google Scholar
  16. [16]
    Mannebach, H., Ohlmeier, H., v. Möllendorf, E., Gleichmann, U., Abshagen, U. (1981), Steady-state Kinetik von Isosorbid-5-Mononitrat bei Patienten mit koronarer Herzkrankheit. Med. Welt 32: 517–520.PubMedGoogle Scholar
  17. [17]
    Fung, H. L., Parker, J. O. (1983), Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris. Br. J. Clin. Pharmacol. 15: 746–748.PubMedGoogle Scholar
  18. [18]
    Fung, H. L., McNiff, E. F., Ruggirello, D., Darke, A., Thadani, U., Parker, J. O. (1981), Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br. J. Clin. Pharmacol. 11: 579–590.PubMedGoogle Scholar
  19. [19]
    Shane, S. J., Iazzetta, J. J., Chisholm, A. W., Berka, J. F., Leung, D. (1978), Plasma concentrations of isosorbide dinitrate and its metabolites after chronic high oral dosage in man. Br. J. Clin. Pharmac. 6: 37–41.Google Scholar
  20. [20]
    Bruyneel, K., Rosseel, M. T., Bogaert, M. G. (1982), Plasma concentrations of isosorbide dinitrate and mononitrates after acute and chronic oral administration of isosorbide dinitrate in man. Arzneimittelforsch/Drug Res.Google Scholar
  21. [21]
    Morrison, R. A., Wiegand, U. W., Jähnchen, E., Höhmann, D., Kasper, W., Meinertz, T., Fung, H. L. (1983b), Hepatic extraction of isosorbide dinitrate in cardiac patients. Clin. Pharmacol. Ther. 34: 724–731.PubMedCrossRefGoogle Scholar
  22. [22]
    Taylor, T., Chasseaud, L. F., Major, R., Doyle, E. (1981). Isosorbide-5-mononitrate pharmacokinetics in humans. Biopharm. Drug Dispos. 2: 255–263.PubMedCrossRefGoogle Scholar
  23. [23]
    Bogaert, M. G., Rosseel, M. T. (1983), Fate of orally given isosorbide dinitrate in man: factors of variability. Z. Kardiol. 72: 11–13.PubMedGoogle Scholar
  24. [24]
    Thadani, U., Darke, A. C., Fung, H. L., Parker, J. O. (1980a), Dose response and duration of action of oral isosorbide dinitrate (ISDN) during sustained therapy in angina pectoris. Am. J. Cardiol. 45: 478.Google Scholar
  25. [25]
    Thadani, U., Fung, H. L., Darke, A. C., Parker, J. O. (1980b), Oral isosorbide dinitrate in the treatment of angina pectoris. Dose response relationship and duration of action during acute therapy. Circulation 62: 491–502.PubMedGoogle Scholar
  26. [26]
    Thadani, U., Manyari, D., Parker, J. O., Fung, H. L. (1980c), Tolerance to the circulatory effects of oral isosorbide dinitrate. Its rate of development and cross tolerance to glyceryl trinitrate. Circulation 61: 526–535.PubMedGoogle Scholar
  27. [27]
    Abshagen, U., Betzien, G., Endele, R., Kaufmann, B. (1981a): Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur. J. Clin. Pharmacol. 20: 269–275.PubMedCrossRefGoogle Scholar
  28. [28]
    Abshagen, U., Demmer, F. (1981): Vorteile und Probleme von Retardpräparaten. Med. Klin. 76: 484–490.PubMedGoogle Scholar
  29. [29]
    Luckow, V., Jansen, W., Osterspey, A. (1984), Pharmakokinetik von Isosorbid-5-Mononitrat nach Gabe einer neuartigen Retardformulierung. Herz/Kreisl. Sonderausgabe: Neue Aspekte, 62-65.Google Scholar
  30. [30]
    Taylor, T., Major, R. M., Leaf, F. C., Cook, S. C., Chasseaud, L. F., Darragh, A. und Lambe, R. F. (1984), Freisetzung von Isosorbid-5-Mononitrat aus Retard-Formulierungen. Arzneim.Forsch./Drug Res. 34(II): 1584–1587.Google Scholar
  31. [31]
    Abshagen, U., Spörl-Radun, S., Betzien, G., Kaufmann, B., Endele, R. (1981b): Pharmakokinetik, Wirkung und Verträglichkeit von Isosorbiddinitrat und Isosorbid-5-Mononitrat bei gesunden Versuchspersonen. Med. Welt 32/14a: 508–516.Google Scholar
  32. [32]
    Reifart, N., Bussmann, W. D., Schirmer, M., Kaltenbach, M. (1981), Hämodynamische Wirksamkeit, Wirkdauer und Pharmakokinetik von 80 mg Isosorbid-5-Mononitrat bei frischem Herzinfarkt. Med. Welt 32: 540–542.PubMedGoogle Scholar
  33. [33]
    Blasini, R., Reiniger, G., Brügmann, U., Rudolph, W. (1984), Vermeidung einer Toleranzentwicklung unter Isosorbiddinitrat durch Intervalltherapie. Herz 9: 166–170 (Nr. 3).PubMedGoogle Scholar
  34. [34]
    Jansen, W., Tauchert, M., Osterspey, A., Hombach, V., Fuchs, M. and Hilger, H. (1983), Long-term treatment of patients with coronary heart disease using isosorbide dinitrate, nifedipine and molsidomine. Z. Kardiol. 72, Suppl. 3: 203–210.Google Scholar
  35. [35]
    Reiniger, G., Blasini, R., Brügmann, U., Rudolph, W. (1984), Toleranzentwicklung hinsichtlich der antiischämischen Wirkung von Isosorbiddinitrat bei regelmäßiger, mehrfach täglicher Verabreichung. Herz 9: 146–152.PubMedGoogle Scholar
  36. [36]
    Thadani, U., Fung, H. L., Darke, A. C., Parker, J. O. (1982), Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am. J. Cardiol. 49: 411–419.PubMedCrossRefGoogle Scholar
  37. [37]
    Rennhak, U., Riebesel, T., and Biamino, G. (1985), A double-blind cross-over study of the effectiveness and possible development of tolerance during long-term therapy with isosorbide-5-mononitrate or isosorbide dinitrate slow release in coronary artery disease. In: J. N. Cohn and R. Rittinghausen (eds.), Mononitrates (International Boehringer Mannheim Symposia, Montreux 1984), Springer-Verlag Berlin, Heidelberg, New York, Tokyo, 147–153.Google Scholar
  38. [38]
    Jansen, W., Tauchert, M., Osterspey, A., and Hilger, H. H. (1985), Comparison of the hemodynamic effects of various doses of isosorbide-5-mononitrate following single-dose and long-term administration in patients with coronary heart disease. In: J. N. Cohn and R. Rittinghausen (eds.), Mononitrates (International Boehringer Mannheim Symposia, Montreux 1984), Springer-Verlag Berlin, Heidelberg, New York, Tokyo, 171–187.Google Scholar
  39. [39]
    Müller, G., Überbacher, J.H., Glocke, M. (1983), Koronartherapeutische Wirksamkeit von niedrig dosiertem IS-5-MN im Vergleich zur Kombination IS-5-MN + Metipranolol and Plazebo. Med. Welt 34: 321–327.PubMedGoogle Scholar
  40. [40]
    Ohlmeier, H., Mertens, H. M., Mannebach, H., and Gleichmann, U. (1985a). Tolerance and Rebound Phenomena in Nitrate Therapy. In: J. N. Cohn and R. Rittinghausen (eds.), Mononitrates (International Boehringer Mannheim Symposia, Montreux 1984), Springer-Verlag Berlin, Heidelberg, New York, Tokyo, 107–123.Google Scholar
  41. [41]
    Schneider, W., Wietschorek, A., Bussmann, W. D., Kaltenbach, M. (1983), Sustained antianginal efficacy of oral high-dose isosorbide dinitrate in patients with coronary heart disease. Z. Kardiol. Suppl. 3, 72: 259–267.PubMedGoogle Scholar
  42. [42]
    Needleman, P., (1975), Biotransformation of organic nitrates. In: Needleman, P. (ed.), Organic Nitrates, Springer-Verlag Berlin, Heidelberg, New York, (Handbook of experimental pharmacology), Vol. 40, 57–95.Google Scholar
  43. [43]
    Needleman, P., Lang, S., Johnson, E. M. Jr., (1972), Organic Nitrates: Relationship between biotransformation and rational angina pectoris therapy. J. Pharmacol. Exp. Ther. 181: 489–497.PubMedGoogle Scholar
  44. [44]
    Aronow, W. S. (1975), Use of nitrates as antianginal agents. In: Needleman (ed.), Organic Nitrates, Springer-Verlag Berlin, Heidelberg, New York (Handbook of experimental pharmacology), Vol. 40, 163–174.Google Scholar
  45. [45]
    Silber, S., Krause, K., Garner, Ch., Theisen, K., Jahrmärker, H. (1983), Anti-ischemic effects of an 80 mg tablet of isosorbide dinitrate in sustained-release form before and after 2 weeks treatment with 80 mg once daily or twice daily. Z. Kardiol. Suppl. 3, 72: 211–217.PubMedGoogle Scholar
  46. [46]
    Ohlmeier, H., Mertens, H., Möller, M., Mannebach, H., Gleichmann, U. (1985b), Akut-und Langzeitwirkung hochdosierter Einmal-Therapie mit 120 mg retardiertem Isosorbiddinitrat. Z. Kardiol. Suppl. 3, 74: 82 (abstract P295).Google Scholar
  47. [47]
    Rudolph, W., Dirschinger, J., Kraus, F., Blasini, R., Reiniger, G., Hall, D. (1984), Behandlung der Angina pectoris mit Nitraten. Med. Klin. 79: 564–569.Google Scholar
  48. [48]
    Silber, S. (1985), Clinical relevance of nitrate tolerance. In: Mononitrates (International Boehringer Mannheim Symposia, Montreux (1984), J.N. Cohn, and R. Rittinghausen (eds.), Springer-Verlag Berlin, Heidelberg, New York, Tokyo 130–146.Google Scholar
  49. [49]
    Schang, St. J., Pepine, C. J. (1977), Transient asymptomatic S-T segment depression during daily activity. Am. J. Cardiol. 39: 396–402.PubMedCrossRefGoogle Scholar
  50. [50]
    Cohn, P. F., Harris, Ph., Barry, W. H., Rosati, R. A., Rosenbaum, P., Waternaux, Ch. (1981), Prognostic importance of anginal symptoms in angiographically defined coronary artery diease. Am. J. Cardiol. 47: 233–237.PubMedCrossRefGoogle Scholar
  51. [51]
    Cohn, P. F. (1983), Silent myocardial ischemia To treat or not to treat. Hospital Practice 125-136.Google Scholar
  52. [52]
    Cohn, P. F. (1985), Myocardial ischemia without angina: Clinical picture and recognition. In Diagnosis of myocardial ischemia in man (symposium) Pisa, in press, (abstract 8).Google Scholar
  53. [53]
    Cocco, G., Braun, S., Strozzi, C., Leishman, B. Chu, D., Rochat, N. (1982), Asymptomatic myocardial ischemia in patients with stable and typical angina pectoris. Clin. Cardiol. 5: 403–408.PubMedCrossRefGoogle Scholar
  54. [54]
    Deanfield, J., Fox, K., Ribeiro, P., Crean, P. Chierchia, S., Maseri, A. (1982), Instability of “stable angina pectoris”, Circulation 66 Suppl. II: 17.Google Scholar
  55. [55]
    Nademanee, K., Intarachot, V., Singh, B. (1983), Compact analog Holter analysis of transient myocardial ischemia in exercise-induced angina. A significant technique for monitoring and guiding anginal therapy (abstract) Circulation 68, suppl. III: 409.Google Scholar
  56. [56]
    Parodi, O., Marzullo, P., Neglia, D., Marcassa, C. (1985), Clinical application of monitoring techniques: Radioisotopic techniques. In: Diagnosis of myocardial ischemia in man (symposium) Pisa, in press, (abstract 22).Google Scholar
  57. [57]
    Bertrand, M. E. (1985), Angiographic findings during transient myocardial ischemia (1985), Diagnosis of myocardial Ischemia in man (Symposium), Pisa, in press, (contribution 31).Google Scholar
  58. [58]
    Waters, D. D. (1985), Problems related to the detection of myocardial ischemia caused by coronary vasospasm. In: Diagnosis of myocardial ischemia in man (symposium) Pisa, in press, (abstract 25).Google Scholar
  59. [59]
    Kaski, J.C., Sykora, J., Rodriguez-Plaza, L., Ratcliffe, D., Stanbridge, R., Taylor, K., Maseri, A. (1985). Asymptomatic episodes of ST segment depression during Holter monitoring disappear after successful coronary bypass. In: Diagnosis of myocardial ischemia in man (symposium) Pisa, in press, (poster 16).Google Scholar
  60. [60]
    Novo, S., Alaimo, G., Giordano, U., Strano, A. (1985), Asymptomatic episodes of ischaemia with and without heart rate changes in patients with effort angina pectoris. In: Diagnosis of myocardial ischemia in man (symposium), Pisa, in press, (poster 26).Google Scholar
  61. [61]
    Thadani, U., Hamilton, S., Teague, S., Brady, D., White, B. (1985), Slow release isosorbide-5-mononitrate in angina pectoris: Rapid development of tolerance to antianginal effects. In: Cardiovascular Pharmacotherapy, Int. Symposium 1985, Genf, Abstract 562.Google Scholar
  62. [62]
    Blasini, R., Brügmann, U., Mannes, A., Froer, K. L., Hall, D., Rudolph, W. (1980), Wirksamkeit von Isosorbiddinitrat in retardierter Form bei Langzeitbehandlung. Herz 5: 298–305.PubMedGoogle Scholar
  63. [63]
    Weidemann, H., Schuon, J. and Schober, B. (1983), Hemodynamic measurements and exercise testing to assess the development of tolerance against slow release isosorbide dinitrate. Z. Kardiol. 72, Suppl. 3: 229–232.Google Scholar
  64. [64]
    Kenedi, P. and Giebeler (1983), Antianginal efficacy of long-term nitrate therapy. Z. Kardiol. 72, Suppl. 3: 233–238.Google Scholar
  65. [65]
    Ignarro, L. J., Kadowitz, P. J., Baricos, W. H. (1981), Evidence that regulation of hepatic guanylate cyclase activity involves interactions between catalytic site-SH groups and both substrate and activator. Arch. Biochem. Biophys. 2: 75–86.CrossRefGoogle Scholar
  66. [66]
    Abshagen, U. (1985c), Organic Nitrates. In: Handbook of Experimental Pharmacology, Vol. 76 (Ed. U. Abshagen), Springer-Verlag Berlin, Heidelberg, New York, Tokyo, 287–364.Google Scholar
  67. [67]
    Neuhaus, R. (1985), Untersuchung zur therapeutischen Äquivalenz von IS-5-MN and ISDN retard. Vorgetragen in: 3. Mononitrat-Work-shop. Kronberg, März 84 (nach Angaben des Autors: Publikation in Vorbereitung).Google Scholar
  68. [68]
    Steinorth, G., Seidel, U., Glocke, M., Überbacher, H. J. (1985), Zur koronartherapeuti-schen Wirksamkeit von IS-5-MN und ISDN retard. Med. Welt 36: 359–366.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH, Braunschweig 1986

Authors and Affiliations

  • U. Abshagen
  • H.-J. Überbacher

There are no affiliations available

Personalised recommendations